Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan N Constantinescu

Showing results (1-10 of 153) with videos related to

Pageof 16
Sort By:
Blood|February 21, 2009
Mpl and thrombocytosis: levels matterStefan N Constantinescu
Biophysical Journal|December 4, 2014
Gathering support for critical mass: interleukin 4 receptor signaling requires clustering in endosomesStefan N Constantinescu
Journal of Cellular and Molecular Medicine|January 26, 2017
Journal of Cellular and Molecular Medicine: the FutureStefan N Constantinescu
Journal of Cellular and Molecular Medicine|February 3, 2009
A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screensStefan N Constantinescu
Current Hematologic Malignancy Reports|September 16, 2015
Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin MutationsXavier Cahu, Stefan N Constantinescu
JAK-STAT|September 24, 2013
The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspectiveJudith Staerk, Stefan N Constantinescu
Hematology. American Society of Hematology. Education Program|November 24, 2005
A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseasesWilliam Vainchenker, Stefan N Constantinescu
Blood|December 9, 2021
Degrading JAK2 in ALL by ruxolitinib-based PROTACsStefan N Constantinescu, Christian Pecquet
Blood|June 13, 2024
DNMT3A gates IFN-induced MPN HSC exhaustionStefan N Constantinescu, William Vainchenker
Hematology. American Society of Hematology. Education Program|December 13, 2012
Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?Stefan N Constantinescu, William Vainchenker
Pageof 16

Showing results (1-10 of 153) with videos related to

Sort By:
Pageof 16
Blood|February 21, 2009
Mpl and thrombocytosis: levels matterStefan N Constantinescu
Biophysical Journal|December 4, 2014
Gathering support for critical mass: interleukin 4 receptor signaling requires clustering in endosomesStefan N Constantinescu
Journal of Cellular and Molecular Medicine|January 26, 2017
Journal of Cellular and Molecular Medicine: the FutureStefan N Constantinescu
Journal of Cellular and Molecular Medicine|February 3, 2009
A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screensStefan N Constantinescu
Current Hematologic Malignancy Reports|September 16, 2015
Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin MutationsXavier Cahu, Stefan N Constantinescu
JAK-STAT|September 24, 2013
The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspectiveJudith Staerk, Stefan N Constantinescu
Hematology. American Society of Hematology. Education Program|November 24, 2005
A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseasesWilliam Vainchenker, Stefan N Constantinescu
Blood|December 9, 2021
Degrading JAK2 in ALL by ruxolitinib-based PROTACsStefan N Constantinescu, Christian Pecquet
Blood|June 13, 2024
DNMT3A gates IFN-induced MPN HSC exhaustionStefan N Constantinescu, William Vainchenker
Hematology. American Society of Hematology. Education Program|December 13, 2012
Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?Stefan N Constantinescu, William Vainchenker
Pageof 16